...
机译:扩展(Q)SARS纳入专有的监管目的知识:使用芳族胺致致胺致突变性的案例研究
AstraZeneca Molndal Sweden;
Sanofi Aventis Deutschland GmbH Frankfurt Germany;
Toxicol Solut San Diego CA USA;
Leadscope Columbus OH USA;
Leadscope Columbus OH USA;
Bristol Myers Squibb Co New Brunswick NJ USA;
Genentech Inc San Francisco CA USA;
Janssen Res &
Dev Beerse Belgium;
GlaxoSmithKline Ware Herts England;
Natl Inst Hlth Sci Tokyo Japan;
Eli Lilly &
Co Indianapolis IN 46285 USA;
European Commiss Joint Res Ctr Ispra Italy;
Vertex Boston MA USA;
Pfizer Groton CT USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
Bayer HealthCare Berlin Germany;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
Incyte Corp Wilmington DE USA;
Incyte Corp Wilmington DE USA;
AstraZeneca Macclesfield Cheshire England;
GlaxoSmithKline Ware Herts England;
Bayer HealthCare Berlin Germany;
Eli Lilly &
Co Indianapolis IN 46285 USA;
Leadscope Columbus OH USA;
ICH M7; Pharmaceutical impurities; Mutagenicity; (Q)SAR; Aromatic amines; SAR fingerprint;
机译:扩展(Q)SAR并纳入专有知识以用于监管目的:使用芳香胺诱变的案例研究
机译:扩展(Q)SARS纳入专有的监管目的知识:使用芳族胺致致胺致突变性的案例研究
机译:扩展(Q)SARS为监管目的合并专有知识:是芳香族N-氧化物是预测DNA-反应性致突变度的结构警报吗?
机译:将芳香胺废品和重金属盐回收成多用途无毒产品的新技术
机译:一个比较定量的构效关系的案例研究对具有机械意义的芳香胺的致突变力。
机译:自信地预测芳香胺的致突变性:使用保形预测的案例研究
机译:令人信心地预测芳香胺崩溃性:使用保形预测的案例研究